https://www.selleckchem.com/pr....oducts/gilteritinib-
Neither the primary nor secondary endpoints differed between the two treatment arms (p=0.90 and p=0.20, respectively). DAR-901 IGRA converters had median responses to ESAT-6 of 50.1 spot-forming cells (SFCs) vs. 19.6 SFCs in placebo IGRA converters (p=0.03). A three-dose series of 1mg DAR-901 was safe and well-tolerated but did not prevent initial or persistent IGRA conversion. DAR-901 recipients with IGRA conversion demonstrated enhanced immune responses to ESAT-6. Since protection against disease may require different imm
Like
Comment
Share
